Investment, Funding & Disinvestments

Today, Equity Afya serves an average of 130,000 patients every month and has grown into one of Africa’s largest franchised primary healthcare networks.

The agreement brings together Protillion’s computational biology platform with Merck’s established drug development expertise to support the discovery of next-generation therapies.

The latest upgrades follow the recent arrival of advanced multi-energy radiotherapy machines destined for Mpilo and Parirenyatwa hospitals, part of a broader government initiative to improve access to specialised cancer treatment across Zimbabwe.

The agreements aim to strengthen national health security and create a coordinated response system that can manage future emergencies more effectively.

The investment forms part of the company’s broader plan to spend US$55 billion on expanding its domestic manufacturing footprint through 2029.

The deal combines acquisition with a concurrent private placement of up to US$64 million in gross proceeds before expenses, strengthening development funding.

Scientia Vascular develops advanced access products designed to improve simplicity and precision during neurovascular interventions.

The designation highlights Abu Dhabi’s expanding role in global health security, particularly in strengthening systems that detect, track, and respond to infectious disease threats.

The partnership grants Lilly global rights to AlzeCure’s preclinical small-molecule candidate, ACD680, which targets the biology of Alzheimer’s disease.

The Hatfield facility, located north of London, will undergo a phased upgrade that will significantly expand its manufacturing, packaging and distribution capabilities.